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Abstract: We studied 21 COPD patients in stable clinical conditions to evaluate whether 
changes in lung function induced by cumulative doses of salbutamol alter diffusing capacity 
for carbon monoxide (DLCO), and whether this relates to the extent of emphysema as assessed 
by high resolution computed tomography (HRCT) quantitative analysis. Spirometry and DLCO 
were measured before and after cumulative doses of inhaled salbutamol (from 200 μg to 1000 
μg). Salbutamol caused signiﬁ  cant increments of forced vital capacity (FVC), forced expiratory 
volume in one second (FEV1), and ﬂ  ows at 30% of control FVC taken from both partial and 
maximal forced expiratory maneuvers. Functional residual capacity and residual volume were 
reduced, while total lung capacity did not change signiﬁ  cantly. DLCO increased progressively with 
the incremental doses of salbutamol, but this became signiﬁ  cant only at the highest dose (1000 
μg) and was independent of the extent of emphysema, as assessed by radiological parameters. 
No signiﬁ  cant changes were observed in CO transfer factor (DLCO/VA) and alveolar volume 
(VA). The results suggest that changes in lung function induced by cumulative doses of inhaled 
salbutamol are associated with a slight but signiﬁ  cant increase in DLCO irrespective of the 
presence and extent of emphysema. 
Keywords: lung volumes, high resolution computed tomography, chronic obstructive bronchitis, 
emphysema
Introduction
In chronic obstructive pulmonary disease (COPD) carbon monoxide uptake in the lung 
(DLCO) is determined to assess the associated presence of emphysema (Pauwels et al 
2001). Reduction of the parameter is deemed to be due to functional and/or anatomical 
reductions of the alveolar and capillary surfaces available for gas exchange (Krogh 
1915; Cadigan et al 1961; Rose et al 1979). For bronchodilator therapy may improve 
lung volume recruitment as a result of a decrease in RV in both chronic obstructive 
bronchitis and emphysema (Cerveri et al 2000), and thus increase the amount of gas 
inhaled with a single inspiration, it would be reasonable to expect an increase in DLCO 
in COPD after bronchodilatation. However, the few studies conducted in this regard 
gave contrasting results. Two studies demonstrated that at least for diagnostic pur-
poses, the test may be safely performed either before or after dilator agonists (Jones 
et al 1961; Chinn et al 1988), whereas a study showed a signiﬁ  cant increase in DLCO 
with inhaled terbutaline 1.5 mg (Åkesson et al 2000). Part of these discrepancies could 
be explained by the different degree of bronchodilatation achieved with different 
pharmacological agents and/or the variable association of emphysema with chronic 
obstructive bronchitis in COPD, both possibly affecting the DLCO measurement as a 
result of different lung volume and pulmonary vascular bed recruitment.
Gaining information on the effects of the bronchodilator agents on the test is 
clinically relevant as DLCO is a functional marker of the progression of a disease 
treated with different therapeutic protocols and doses of beta-2 agonists. Indeed, the International Journal of COPD 2006:1(4) 478
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variable course of the disease and/or the chronic effects of 
bronchodilator therapy may lead to recruitment of alveolar 
volume within lung regions previously served by closed or 
near-closed airways and/or improvement of blood perfusion 
across the lung over time, thus potentially affecting the DLCO 
and its interpretation.
On this ground, we wondered whether DLCO varies with 
the degree of pharmacologically-induced bronchodilatation 
and/or extent of emphysema in COPD.
To test this hypothesis, we studied lung function and 
diffusing capacity before and after cumulative doses of 
inhaled salbutamol. The study was conducted in a group of 21 
COPD patients well characterized for degree of emphysema, 
as assessed by radiological criteria.
Methods
Patients
Eighteen male and tree female patients affected by COPD, as 
deﬁ  ned by the international guidelines (Pauwels et al 2001) 
participated in the study (Table 1). Six of them were current 
smokers and ﬁ  fteen former smokers, with an average smoking 
history of 51.6 ± 18.8 pack-years. Airﬂ  ow obstruction ranged 
from moderately severe to very severe. All patients were required 
to abstain from short-acting bronchodilators for at least 12 h prior 
to each study session, to be in stable clinical conditions, and not 
to have suffered from respiratory exacerbation in the previous 
four weeks. The Ethics Committee approved the experimental 
protocol, and a written informed consent was obtained prior to 
the study from each subject.
Study design
The patients attended the laboratory in the morning of two 
separate days. On the ﬁ  rst day, absolute lung volumes, DLCO, 
and partial (PEFV) and maximal (MEFV) ﬂ  ow-volume 
curves were measured at baseline (Step 1). The same 
measurements were repeated in the same order 15 min after 
each of the following sequential doses of salbutamol given 
through a spacer by metered dose inhaler: 200 μg (Step 2), 
400 μg (Step 3), and 400μg (Step 4). The doses were chosen 
to cover at least part of the broad range of bronchodilator 
responses reported in COPD (Anthonisen et al 1986; 
Calverley et al 2003). On the second day, a high resolution 
computed tomography (HRCT) of the lung was obtained.
Lung function measurements
Inspired and expired volumes were obtained by numerical 
integration of mouth ﬂ  ow measured by a mass ﬂ  ow sensor 
(Sensor Medics, Yorba Linda, CA). After at least 8 regular 
tidal breaths, the patients were asked to expire forcefully from 
about 60% of vital capacity (VC) to residual volume (RV) 
(PEFV maneuver), to rapidly inspire to total lung capacity 
(TLC), and forcefully expire to RV (MEFV maneuver) without 
breath hold. The latter allowed the forced expiratory volume 
in one second (FEV1) and forced vital capacity (FVC) to be 
computed. At least three technically acceptable curves were 
recorded. Flows at 30% of control FVC were taken on MEFV 
(V
.
 max30) and PEFV (V
.
 part30) curves.
Lung volumes were measured with the patients sitting in 
a body plethysmograph (Jaeger Masterlab, Jaeger, Würzburg, 
Germany) and panting against a closed shutter at a frequency 
slightly <1 Hz, cheeks supported by hands. TLC was obtained as 
the sum of thoracic gas volume (TGV) and the linked inspiratory 
capacity. Functional residual capacity (FRC) was obtained from 
TGV corrected for any difference between the volume at which 
the shutter was closed and the average end-expiratory volume of 
the four preceding regular tidal breaths. RV was the difference 
between TLC and VC. Predicted values for spirometry and lung 
volume are from Quanjer and colleagues (1979).
DLCO was measured according to the American Thoracic 
Society (ATS) recommendations (Crapo et al 1995) with a 
Baires System (Biomedin, Padua, Italy), using a gas mixture 
of 0.3% CO, 10% helium, and balance air. Breath holding 
time was measured by the method of Jones-Meade (Jones and 
Meade 1961). At each step of the study, two measurements 
of DLCO were made at a 4-min interval and were accepted if 
their inspired volumes were within 0.2 L between each other 
and 10% of the VC measured by spirometry. Adjustment 
for carboxyhemoglobin (HbCO) to account for the effect 
of increasing CO concentrations, and adjustment for Hb 
concentrations with repeated DLCO measurements were done 
according to the ATS statement (ATS 1987) in 10 patients 
who had their arterial blood drawn at the four steps of the 
study. In the other 11 patients, DLCO was corrected for the 
average slope of the linear regression analysis of DLCO 
adjusted versus nonadjusted for HbCO in the 10 patients. 
Reference values for DLCO are from Cotes (1979).
Imaging
Lung HRCT was performed with a third-generation, 
continuous-rotation-computerized tomograph with single scan 
acquisition (Somaton Plus, Siemens, Erlangen, Germany). 
Technical parameters were the following: 1mm collimation, 
137 kVp, 195 mAs, and <1s scanning time. The lungs were 
scanned from the apex through the base at 1cm intervals and 
reconstructed with a lung algorithm. International Journal of COPD 2006:1(4) 479
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All scan images were processed off-line using a semi-
automated image-processing program, which extracts 
boundaries of the lungs, calculates lung cross sectional 
areas and histograms of attenuation values (CT numbers) of 
individual highlighted sections, and summarizes data to obtain 
the frequency distribution of attenuation values for both lungs. 
From the frequency distribution of CT numbers, mean CT 
number in Hounsﬁ  eld units (HU) were derived. Percent of the 
whole lung area with attenuation values lower than –950 HU 
(RA950) was taken as an index of extent of emphysema 
(Gevenois et al 1995, 1996).
Statistical analysis
Data are expressed as mean ± standard deviation. Relationships 
between variables were tested by linear regression analysis. 
Analysis of variance (ANOVA) for repeated measures was 
used to compare the effects of increasing doses of salbutamol 
at the different steps. When F values were signiﬁ  cant, Tukey’s 
post hoc test was used for multiple comparisons. P < 0.05 was 
considered statistically signiﬁ  cant.
Results
The severity of airway obstruction, based on spirometric data, 
ranged from moderate to very severe (Table 1). Emphysema 
was variably present, as suggested by the wide ranges of RA950, 
lung hyperinﬂ  ation and DLCO (Table 1).
Seventeen patients completed the four steps of study, and 
four asked to interrupt the test at step 3 after a cumulative 
dose of 600 μg. Increasing the dose of salbutamol caused 
a progressive and signiﬁ  cant increase in V
. 
max30, V
.
 part30, 
FEV1, and FVC, and a decrease in FRC and RV, consist-
ent with effective bronchodilatation and decrease in lung 
hyperinﬂ  ation (Table 2). Average DLCO progressively in-
creased with bronchodilatation, but this became signiﬁ  cant 
only with the highest dose of salbutamol (p < 0.05) (Table 
2). In contrast, no signiﬁ  cant changes occurred in VA and 
DLCO/VA (Table 2).
The slopes of linear regression analysis of DLCO 
plotted against FEV1, VC, and FRC at the four steps in 
individual patients were significantly different from 0 
Table 1 Main anthropometric, functional, and imaging data
  Mean ± SD  Range
Age, yr  69 ± 8  54–84
BMI, Kg/m2  27 ± 4  19–34
FEV1, % pred  45 ± 16  19–69
VC, % pred  76 ± 19  40–123
FRC, % pred  156 ± 32  104–223
RV, % pred  176 ± 49  120–288
TLC, % pred  112 ± 14  93–145
DLCO, % pred  57 ± 23  24–105
DLCO/VA, % pred  50 ± 19  21–108
PaCO2, mmHg  37 ± 4  27–44
PaO2, mmHg  66 ± 8  52–76
Hb, g/dl  14 ± 2  12–17
RA950, %  19 ± 7  6–31
Notes: Data are means ± SD.
Abbreviations: BMI, body mass index; DLCO, carbon monoxide diffusing capacity; 
FEV1, forced expiratory volume in one second; FRC, functional residual capacity; 
RV, residual volume; SD, standard deviation; TLC, total lung capacity; VC, vital 
capacity; VA, alveolar volume; PaCO2, arterial carbon dioxide tension; PaO2, arterial 
oxygen tension; Hb, hemoglobin; RA950, lung area with attenuation values lower 
than –950 HU. 
Table 2 Main respiratory functional parameters at baseline and after additional doses of salbutamol
  STEP 1  STEP 2  STEP 3  STEP 4
 Baseline  200  μg 600  μg 1000  μg
Subjects, no.  21  21  21  17
FEV1, L  1.14 ± 0.40  1.26 ± 0.43c  1.32 ± 0.45c  1.42 ± 0.50c
FVC, L  2.55 ± 0.88  2.83 ± 0.93c  2.97 ± 0.97c  3.02 ± 1.03c
V
.
 max30, L/s  0.24 ± 0.15  0.29 ± 0.21  0.35 ± 0.27c  0.36 ± 0.24c
V
.
 part30, L/s  0.42 ± 0.21  0.51 ± 0.24  0.54 ± 0.29c  0.57 ± 0.28c
VC, L  2.65 ± 0.85  2.98 ± 0.89c  3.14 ± 0.97c  3.36 ± 1.08c
FRC, L  5.28 ± 1.42  5.02 ± 1.40c  4.85 ± 1.34c 4.72±1.30c
RV, L  4.22 ± 1.35  3.96 ± 1.31c  3.82 ± 1.32c  3.59 ± 1.35c
TLC, L  6.92 ± 1.54  6.94 ± 1.57  6.95 ± 1.57  6.97 ± 1.50
HbCOa, %  2.3 ± 0.6  3.3 ± 0.6c  4.3 ± 0.6c  5.2 ± 0.7c
VA, L  4.93 ± 1.00  5.17 ± 1.06  5.05 ± 1.03  5.15 ± 1.07
DLCO, ml/mmHg/min/L  14.35 ± 5.07  15.12 ± 4.81  15.72 ± 4.95  16.41 ± 5.02b
DLCO/VA, ml/mmHg/min/L  3.03 ± 1.20  3.07 ± 1.17  3.21 ± 1.08  3.23 ± 1.06
Note: aHbCO, carboxyhemoglobin measured in 10 patients; bp < 0.05; cp < 0.01 or less versus baseline; Data are means ± SD.
Abbreviations: DLCO, carbon monoxide diffusing capacity; FEV1, forced expiratory volume in one second; FRC, functional residual capacity; FVC, forced vital capacity; 
RV, residual volume; SD, standard deviation; TLC, total lung capacity; V
.
 max30 and V
.
 part30, maximal and partial forced expiratory ﬂ  ows at 30% control FVC; VA, alveolar 
volume; VC, vital capacity. International Journal of COPD 2006:1(4) 480
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(Table 3 and Figure 1), thus suggesting that DLCO tended 
to increase with bronchodilatation and volume recruit-
ment. In contrast, only the slope of the linear regression 
of DLCO/VA versus FEV1 attained statistical significance 
(Table 3).
Neither of these slopes correlated with the extent of 
emphysema as assessed by HRCT scan, thus suggesting that 
DLCO increased with bronchodilatation irrespective of the 
extent of emphysema, as assessed with imaging techniques 
(Figure 2).
DLCO % pred correlated with the extent of emphysema at 
all 4 steps of the study (Figure 3).
Discussion
The major ﬁ  ndings of the present study on COPD patients are 
that DLCO progressively increased with cumulative doses of 
inhaled salbutamol to become signiﬁ  cant at doses higher 
than those commonly used for clinical treatments. In addi-
tion, this occurred independently of the presence and extent 
of emphysema, as assessed by radiological parameters. VA 
tended to increase, so that DLCO/VA remained unchanged.
Theory predicts that VA, permeability characteristics of 
the alveolar-to-capillary barrier, and ability of hemoglobin to 
combine with CO are the main determinants of DLCO (Krogh 
1915; Cadigan et al 1961; Chinn et al 1988). Therefore, any 
Table 3 Average linear regression slopes of DLCO, and DLCO/
VA versus key variables with inhalation of increasing doses of 
salbutamol.
Variables DLCO DLCO/VA
FEV1  11.8 ± 14.0b  3.6 ± 5.8a
FVC  1.1 ± 11.6  0.01 ± 4.0
V
.
 max30  4.3 ± 25.2  1.9 ± 6.6
V
.
 part30  12.3 ± 35.3  1.8 ± 8.1
VC  3.9 ± 6.0b  1.0 ± 2.6
FRC –3.9  ±  8.1a  –0.6 ± 2.4
Notes: Data are means ± SD; Signiﬁ  cant differences from baseline conditions are 
denoted with symbols: ap < 0.05; bp < 0.01 or less.
Abbreviations: DLCO, carbon monoxide diffusing capacity; FEV1, forced expiratory 
volume in one second; FRC, functional residual capacity; FVC, forced vital capacity; 
SD, standard deviation; V
. 
max30 and V
.
 part30, maximal and forced expiratory ﬂ  ows at 
30% control FVC; VA, alveolar volume; VC, vital capacity.
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Figure 1 Linear regression lines of DLCO versus FEV1 with incremental doses of salbutamol in individual patients. Values are expressed as % of predicted.
Abbreviations: DLCO, carbon monoxide diffusing capacity; FEV1, forced expiratory volume in one second.International Journal of COPD 2006:1(4) 481
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intervention resulting in recruitment of lung volume would 
be expected to increase DLCO. Unexpectedly however, the 
substantial increase in slow VC observed with salbutamol 
in our COPD patients was not associated with a signiﬁ  cant 
increase in DLCO. The increment in VC was due to a decrease 
in RV and not to an increase in TLC, which suggests opening 
of airways previously closed. Had the lack of increase in 
DLCO mostly manifested in patients with low lung elastic 
recoil as in emphysema despite the decrease in RV, this 
would have been presumably the result of opening of airways 
subtending enlarged emphysematous units with disrupted 
vascular component unable to subtract CO from the alveoli. 
The absence of any relationship between changes in DLCO 
and DLCO/VA after salbutamol and HRCT data suggests, 
therefore, additional and/or alternative mechanisms. Among 
them is the possibility that VA was already fully recruited at 
maximal inﬂ  ation even before inhaling the bronchodilator. 
Under these conditions, the effects of the medication on 
bronchial tone were negligible to recruit new VA useful 
for gas exchange. Alternatively, alveolar recruitment with 
salbutamol in COPD occurred in the airways subtending 
alveolar units with hypoxic vasoconstriction. As documented 
in many animal species including humans, a decrease in O2 
tension in the alveolar compartment would cause a local 
increase in pulmonary vascular resistance, as a result of 
narrowing of pre-capillary arteries by mechanisms involving 
K+ and Ca++ channels (Post et al 1992) and enhanced by 
local acidosis (Enson et al 1964). With bronchodilatation 
and ensuing alveolar recruitment, hypoxic vasoconstriction 
might have disappeared and DLCO increased, unless vascular 
reopening lagged behind alveolar reopening.
An additional cause for an increased DLCO with high doses 
of salbutamol might have been the increase in cardiac output 
and the resulting distension of the pulmonary bed. Though 
we do not bring direct evidence for this, the increase in heart 
rate reported in healthy volunteers after doses of salbutamol 
similar to ours (Bremner et al 1993) would suggest that the 
cardiovascular side-effects of high doses of β2 agonists might 
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Figure 2 Relationships between linear regression slopes of DLCO versus FEV1 with increasing doses of salbutamol and extent of emphysema, as assessed by HRCT scan 
quantitative analysis (RA950).
Abbreviations: DLCO, carbon monoxide diffusing capacity; FEV1, forced expiratory volume in one second; HU, Hounsﬁ  eld units; RA950, lung area with attenuation values 
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be indeed capable of increasing cardiac output, thus possibly 
contributing to increase DLCO. Yet, it remains to demonstrate 
that these doses of salbutamol can really do that.
Previous studies have documented that imposing an 
inspiratory resistance in healthy subjects is associated with an 
increase in DLCO, as a result of an increase in pleural pressure 
and ensuing amount of blood shifted from the abdomen to 
the chest wall and lungs (Cotes et al 1960; Smith et al 1969). 
By converse, a decreased inspiratory resistance would be 
expected to lower DLCO. Whether the bronchodilatation 
observed in the present study might have affected DLCO is a 
matter of speculation, though it could have also contributed 
to blunt the expected increase in DLCO.
The fact that DLCO increased with progressive reduction 
in bronchial tone may have some clinical relevance. For 
instance, in clinical trials using this parameter as a functional 
outcome for follow-up or evaluation of the effects of new, 
nonbronchodilator treatments in emphysema, any signiﬁ  cant 
change of DLCO should be taken with cautiousness before 
concluding that this reﬂ  ects a clear disease modiﬁ  cation. In 
contrast, the maintenance of the correlation between DLCO 
as % pred and extent of emphysema (Figure 3) at all 4 steps 
would apparently suggest that the effect of bronchial tone 
on DLCO is insigniﬁ  cant with respect to the diagnosis of the 
disease.
In conclusion, the present study documents that improved 
lung function induced with cumulative doses of inhaled 
salbutamol is associated with a slight but signiﬁ  cant increase in 
DLCO irrespective of the presence and extent of emphysema. 
These ﬁ  ndings implicate that changes in DLCO over time, as 
observed in clinical or therapeutic trials, may be at least in 
part affected by changes in airway caliber.
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